Singapore, 24 January 2017 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it will be presenting at the 2017 Cholangiocarcinoma Foundation Annual Conference in Salt Lake City, Utah.
Organised by The Cholangiocarcinoma Foundation, the annual conference, which will be held from 1 to 3 February 2017, brings together healthcare professionals, researchers and policymakers, as well as patients and their caregivers, in a dedicated forum that encourages the engagement of the medical and research communities on cholangiocarcinoma.
Dr Bertil Lindmark, Chief Medical Officer, ASLAN, will deliver a presentation on varlitinib, the Company's lead asset, to members of The International Cholangiocarcinoma Research Network (ICRN) at the event’s Industry Night. Varlitinib, a potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs), has received Orphan Drug Designation for cholangiocarcinoma from the US Food & Drug Administration, and is expected to enter pivotal clinical development this year.
ASLAN is also proud to be a Maple sponsor of the Conference.
For more information on the Annual Conference and Foundation, please visit: http://cholangiocarcinoma.org/.
Organised by The Cholangiocarcinoma Foundation, the annual conference, which will be held from 1 to 3 February 2017, brings together healthcare professionals, researchers and policymakers, as well as patients and their caregivers, in a dedicated forum that encourages the engagement of the medical and research communities on cholangiocarcinoma.
Dr Bertil Lindmark, Chief Medical Officer, ASLAN, will deliver a presentation on varlitinib, the Company's lead asset, to members of The International Cholangiocarcinoma Research Network (ICRN) at the event’s Industry Night. Varlitinib, a potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs), has received Orphan Drug Designation for cholangiocarcinoma from the US Food & Drug Administration, and is expected to enter pivotal clinical development this year.
ASLAN is also proud to be a Maple sponsor of the Conference.
For more information on the Annual Conference and Foundation, please visit: http://cholangiocarcinoma.org/.
